Recent Updates
Recently added Catalysts
SEPN Positive Sentiment

Septerna to Participate in Upcoming Investor Conferences

Key Takeaway: Septerna, Inc. has announced its participation in two upcoming investor conferences in September 2026. The company will engage in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 8 and at the Cantor Global Healthcare Conference on September 10. Live webcasts of these presentations will be available on their website.
Price reaction · baseline $38.15 (2026-08-31 close) · hit pre-market · clean, no other SEPN news in the window
day 0 close · peak
-1.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in notable investor conferences highlights company visibility.
  • Management's engagement indicates confidence in their pipeline and strategy.
  • Live webcasts allow broader access to company updates.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~68 mo
Minimal dilution risk
Lead asset
SEP-631
Phase 1 · Undisclosed

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following investor conferences in September:

Wells Fargo 21 st Annual Healthcare Conference Fireside chat on Tuesday, September 8, 2026, at 8:00 a.m. ET

Cantor Global Healthcare Conference 2026 Fireside chat on Thursday, September 10, 2026, at 11:30 a.m. ET

A live webcast of each presentation will be available in the investors section of the company’s website at www.septerna.com. The webcasts will be archived for at least 30 days following the presentation.
About Septerna Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform ® is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.

Investor Contact: Renee Leck, THRUST renee@thrustsc.com

Media Contact: Carly Scaduto, THRUST carly@thrustsc.com

Frequently Asked Questions

What conferences will Septerna participate in?

Septerna will participate in the Wells Fargo 21st Annual Healthcare Conference and the Cantor Global Healthcare Conference.

When is Septerna's fireside chat at the Wells Fargo conference?

The fireside chat at the Wells Fargo conference is scheduled for September 8, 2026, at 8:00 a.m. ET.

How can I access Septerna's conference presentations?

Live webcasts of Septerna's presentations will be available on their website and archived for 30 days.

What is Septerna's focus in drug development?

Septerna focuses on G protein-coupled receptor therapies for various therapeutic areas, including endocrinology and immunology.

Last updated: Sep 1, 2026